title: Acute rejection of hepatic allografts from HLA-DR13 (Allele DRB1(*)1301)-positive donors.
abstract: Acute rejection of hepatic allografts does not show consistent association with the number of mismatches of HLA classes I and II. Therefore, we investigated the relation between specific donor or recipient HLA antigens and the occurrence of acute rejection. HLA typing of 35 liver transplant recipients and donors was performed by serological standard technique, with confirmation and subtyping by polymerase chain reaction with sequence-specific primers. HLA class I antigens were not associated with the occurrence of acute rejection. The graft was positive for HLA-DR13 in 8 of 13 transplant recipients (62%) with acute rejection, but only 4 of 22 recipients (18%; P =.024; P(Bonferroni-corrected) =.33, not significant) without rejection. The graft was positive for DRB1*1301 in 7 of 13 recipients (54%) with acute rejection, but only 1 of 22 recipients (5%) without rejection (P =.002; P(Bonferroni-corrected )=.028). This patient had experienced long-lasting bacterial sepsis, which markedly reduced the risk for acute rejection. We speculate that the expression of donor DRB1*1301 (if mismatched) may increase the risk for acute hepatic allograft rejection.
authors.affiliation: Department of Medicine II, University of Leipzig, Leipzig, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Oertel
authors.forename: F
authors.initials: F
authors.lastname: Berr
authors.forename: S
authors.initials: S
authors.lastname: Schröder
authors.forename: R
authors.initials: R
authors.lastname: Schwarz
authors.forename: A
authors.initials: A
authors.lastname: Tannapfel
authors.forename: M
authors.initials: M
authors.lastname: Wenzke
authors.forename: P
authors.initials: P
authors.lastname: Lamesch
authors.forename: J
authors.initials: J
authors.lastname: Hauss
authors.forename: K
authors.initials: K
authors.lastname: Kohlhaw
mesh_terms: D000208:Acute Disease; D000328:Adult; D000483:Alleles; D015415:Biomarkers; D001706:Biopsy; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control; D006684:HLA-DR Antigens / Q000235:genetics* / Q000276:immunology; D059810:HLA-DR Serological Subtypes; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016031:Liver Transplantation / Q000276:immunology*; D011379:Prognosis; D011446:Prospective Studies; D012720:Severity of Illness Index; D014019:Tissue Donors; D014184:Transplantation, Homologous
chemical_list: D015415:Biomarkers; D006684:HLA-DR Antigens; D059810:HLA-DR Serological Subtypes; C097337:HLA-DR13 antigen; D007166:Immunosuppressive Agents